PPLPHARMA.NS Profit & Loss
Piramal Pharma Ltd.
Profit & Loss Balance Sheet Cash Flow
Profit & Loss · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 23:43
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Revenue from Operations | ₹7,081.55 Cr. | ₹8,171.16 Cr. | ₹9,151.18 Cr. | ₹8,869.08 Cr. | RevenueFromOperations |
| Gross Revenue (incl. inter-segment) | N/A | N/A | N/A | N/A | SegmentRevenueFromOperations |
| Other Income | ₹225.11 Cr. | ₹175.39 Cr. | ₹134.81 Cr. | ₹213.30 Cr. | OtherIncome |
| Total Income | ₹7,306.66 Cr. | ₹8,346.55 Cr. | ₹9,285.99 Cr. | ₹9,082.38 Cr. | Income |
| Cost of Materials Consumed | ₹1,682.46 Cr. | ₹1,976.83 Cr. | ₹2,055.74 Cr. | ₹1,995.85 Cr. | CostOfMaterialsConsumed |
| Purchases of Stock-in-Trade | ₹952.20 Cr. | ₹1,175.77 Cr. | ₹1,417.32 Cr. | ₹1,430.53 Cr. | PurchasesOfStockInTrade |
| Changes in Inventories | ₹68.64 Cr. | ₹-198.60 Cr. | ₹-241.41 Cr. | ₹-187.84 Cr. | ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade |
| Employee Benefit Expense | ₹1,896.35 Cr. | ₹2,029.50 Cr. | ₹2,307.47 Cr. | ₹2,415.92 Cr. | EmployeeBenefitExpense |
| Finance Costs | ₹344.18 Cr. | ₹448.49 Cr. | ₹421.59 Cr. | ₹340.80 Cr. | FinanceCosts |
| Depreciation and Amortisation | ₹676.69 Cr. | ₹740.57 Cr. | ₹816.34 Cr. | ₹831.24 Cr. | DepreciationDepletionAndAmortisationExpense |
| Other Expenses | ₹1,853.66 Cr. | ₹1,991.40 Cr. | ₹2,167.23 Cr. | ₹2,293.00 Cr. | OtherExpenses |
| Total Expenses | ₹7,474.18 Cr. | ₹8,163.96 Cr. | ₹8,944.28 Cr. | ₹9,119.50 Cr. | Expenses |
| Profit Before Exceptional Items and Tax | ₹-167.52 Cr. | ₹182.59 Cr. | ₹341.71 Cr. | ₹-37.12 Cr. | ProfitBeforeExceptionalItemsAndTax |
| Exceptional Items | ₹-6.96 Cr. | ₹-62.79 Cr. | ₹0.00 Cr. | ₹-196.14 Cr. | ExceptionalItemsBeforeTax |
| Profit Before Tax | ₹-174.48 Cr. | ₹119.80 Cr. | ₹341.71 Cr. | ₹-233.26 Cr. | ProfitBeforeTax |
| Tax Expense | ₹66.31 Cr. | ₹161.47 Cr. | ₹323.51 Cr. | ₹149.88 Cr. | TaxExpense |
| Net Profit (incl. minority interest) | ₹-186.46 Cr. | ₹17.82 Cr. | ₹91.13 Cr. | ₹-325.94 Cr. | ProfitLossForPeriod |
| Net Profit (to shareholders) | N/A | N/A | ₹91.13 Cr. | ₹-325.94 Cr. | ProfitOrLossAttributableToOwnersOfParent |
| Basic EPS | ₹-1.57 | ₹0.14 | ₹0.69 | ₹-2.46 | BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
| Diluted EPS | ₹-1.57 | ₹0.14 | ₹0.68 | ₹-2.46 | DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
Every figure above is the exact value of the named XBRL element from PPLPHARMA.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).